Genmab A (GMAB) Total Non-Current Liabilities (2019 - 2026)
Genmab A (GMAB) reported Total Non-Current Liabilities of $5.5 billion for Q1 2026, up 932.96% on a YoY basis from $534.0 million in Q1 2025, and down 1.48% quarter-over-quarter from $5.6 billion in Q4 2025.
Genmab A (GMAB) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Genmab A has reported Total Non-Current Liabilities for 6 years, with the latest figure at $5.5 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 932.96% year-over-year to $5.5 billion; the trailing twelve-month figure through Mar 2026 stood at $5.5 billion (up 932.96% YoY), and the FY2025 full-year result was $5.6 billion, up 950.47% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $5.5 billion, down from $5.6 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $5.6 billion in Q4 2025, with the low at $177.0 million in Q4 2023.
- Historically, Total Non-Current Liabilities has averaged $1.9 billion across 4 years, with a median of $533.0 million in 2024.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 201.13% — and 2025, when it soared 950.47%.
- Genmab A's Total Non-Current Liabilities stood at $177.0 million in 2023, then soared by 201.13% to $533.0 million in 2024, then soared by 950.47% to $5.6 billion in 2025, then dropped by 1.48% to $5.5 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $5.5 billion (Q1 2026), $5.6 billion (Q4 2025), and $529.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 42,980.09 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 64.76 Mn |
| 10 | Genmab A | 48.34 Bn | 46.82 Bn | 831.00 Mn | 5.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.52 Bn |
| Dec 31, 2025 | 5.60 Bn |
| Sep 30, 2025 | 529.00 Mn |
| Jun 30, 2025 | 533.00 Mn |
| Mar 31, 2025 | 534.00 Mn |
| Dec 31, 2024 | 533.00 Mn |
| Dec 31, 2023 | 177.00 Mn |
| Sep 30, 2020 | 787.00 |
| Dec 31, 2019 | 158.00 |
| Sep 30, 2019 | 160.91 Mn |